The toxicities of modern targeted therapies: learning from the price of progress.
Giles
Francis J
FJ
D001549:Benzamides; D000069439:Dasatinib; D016503:Drug Delivery Systems / Q000009:adverse effects*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D000068877:Imatinib Mesylate; D033183:Interdisciplinary Communication; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D008168:Lung / Q000187:drug effects / Q000473:pathology; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011494:Protein Kinases / Q000378:metabolism; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects; D012867:Skin / Q000187:drug effects / Q000473:pathology; D058570:TOR Serine-Threonine Kinases; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D042461:Vascular Endothelial Growth Factor A; D000068877:Imatinib Mesylate; D011494:Protein Kinases; C546842:MTOR protein, human; D066246:ErbB Receptors; D058570:TOR Serine-Threonine Kinases; C498826:nilotinib; D000069439:Dasatinib; D020123:Sirolimus